Association of Methylenetetrahydrofolate Reductase Gene Polymorphism With Carotid Atherosclerosis Depending on Smoking Status in a Japanese General Population

Background and Purpose— The association of the methylenetetrahydrofolate reductase gene (MTHFR) with carotid atherosclerosis remains inconsistent. This may be due to small sample size and inappropriate analysis. We investigated the association of C677T/MTHFR with blood pressure and carotid atherosclerosis in a Japanese general population. Methods— Subjects (30 to 89 years of age; 1693 women, 1554 men) who gave informed consent were randomly selected from a general population in Suita, Japan. MTHFR genotypes were determined by TaqMan polymerase chain reaction. Carotid atherosclerosis was evaluated by high-resolution ultrasonography with atherosclerotic indexes of intimal-medial thickness (IMT), maximum IMT in the common carotid artery (CCA), plaque score, and stenosis (>50%). Results— Age-adjusted diastolic blood pressure was significantly higher in women with the TT genotype than in those with the CC genotype. In a recessive model (CC +CT versus TT), all adjusted odds ratios for hypertension and >50% stenosis in women were 1.42 and 3.42 (95% confidence intervals, 1.01 to 1.99 and 1.23 to 9.53), respectively. In women, maximum IMT in CCA for smokers with the TT genotype was significantly higher than for smokers with the CC genotype and nonsmokers with the TT genotype (P <0.05). Conclusions— Our study suggests that the MTHFR TT genotype is a risk factor for hypertension and carotid stenosis in women. Significant interactions between C677T/MTHFR and smoking on maximum IMT in CCA were observed in women but not in men. Smoking cessation for subjects with the TT genotype is important in the prevention of cerebrovascular disease.

[1]  Y. Kokubo,et al.  Are the Associations between Life-style Related Factors and Plasma Total Homocysteine Concentration Different According to Polymorphism of 5,10-Methylenetetrahydrofolate Reductase Gene (C677T MTHFR)? , 2002, Journal of epidemiology.

[2]  K. Sumino,et al.  Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. , 2001, The Kobe journal of medical sciences.

[3]  A. Passaro,et al.  Plasma homocysteine, methylenetetrahydrofolate reductase mutation and carotid damage in elderly healthy women. , 2001, Atherosclerosis.

[4]  H. Boeing,et al.  Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam study. , 2001, Metabolism: clinical and experimental.

[5]  D. Giugliano,et al.  Glycemia, MTHFR genotype and low homocysteine in uncomplicated type 2 diabetic patients. , 2000, Atherosclerosis.

[6]  G. Hankey,et al.  Homocysteine and vascular disease , 1999, The Lancet.

[7]  D. Borderie,et al.  Homocysteine decreases endothelin-1 production by cultured human endothelial cells. , 1999, European journal of biochemistry.

[8]  D. Steinberg,et al.  Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Y. Yazaki,et al.  Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. Stanton,et al.  Homocysteine and cardiovascular disease , 2011 .

[11]  A. Gnasso,et al.  Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine and other risk factors for vascular disease. , 1998, Atherosclerosis.

[12]  K. Sutton-Tyrrell,et al.  High homocysteine levels are independently related to isolated systolic hypertension in older adults. , 1997, Circulation.

[13]  T. Raghunathan,et al.  Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. , 1997, Circulation.

[14]  N. Nishi,et al.  Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. , 1997, Stroke.

[15]  S. Vasikaran,et al.  Methylenetetrahydrofolate reductase gene and coronary artery disease. , 1997, Circulation.

[16]  L. Taylor,et al.  Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. , 1996, Circulation.

[17]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. , 1996, Circulation.

[18]  A. Evans,et al.  Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. , 1996, Circulation.

[19]  S. Vollset,et al.  Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study. , 1996, The Journal of clinical investigation.

[20]  J. Yarnell,et al.  The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. , 1996, QJM : monthly journal of the Association of Physicians.

[21]  M. Margaglione,et al.  Elevated total plasma homocysteine and 677C-->T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. , 1996, American journal of human genetics.

[22]  D. Wilcken,et al.  Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[23]  S. Vollset,et al.  Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. , 1995, JAMA.

[24]  J. Genest,et al.  Measurement of homocyst(e)ine in the prediction of arteriosclerosis. , 1995, Clinical biochemistry.

[25]  R. D'Agostino,et al.  Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. , 1995, The New England journal of medicine.

[26]  T H Beaty,et al.  Minimum sample size estimation to detect gene-environment interaction in case-control designs. , 1994, American journal of epidemiology.

[27]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[28]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[29]  W. Willett,et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. , 1992, JAMA.

[30]  R. Clarke,et al.  Hyperhomocysteinemia: an independent risk factor for vascular disease. , 1991, The New England journal of medicine.

[31]  D. Reed,et al.  A prospective study of cerebral artery atherosclerosis. , 1988, Stroke.

[32]  Robert C. Elston,et al.  Biostatistical genetics and genetic epidemiology , 2002 .

[33]  J. Kastelein,et al.  Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. , 1997, Circulation.

[34]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[35]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[36]  J. Spence,et al.  Measurement of atherosclerosis: development of an atherosclerosis severity index. , 1989, Clinical and experimental hypertension. Part A, Theory and practice.